日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma.

rucaparib 联合 PLX038A 治疗浆液性子宫内膜癌的抗肿瘤活性

Hou Xiaonan, Zanfagnin Valentina, Xu Conway, Jessen Erik, Liu Yuanhang, Wang Chen, Huang Yajue, Fontaine Shaun D, Santi Daniel V, Colon-Otero Gerardo, Gill Sarah E, Glaser Gretchen E, Butler Kristina A, Bakkum-Gamez Jamie N, Dowdy Sean C, Oberg Ann L, Larson Melissa C, Atkinson Hunter J, Duffield Laura N, Peterson Kevin L, Kaufmann Scott H, Weroha S John

Management of significant pleural effusion at ovarian cancer diagnosis: Outcomes of triage to neoadjuvant chemotherapy without thoracic assessment

卵巢癌诊断时出现大量胸腔积液的处理:未经胸部评估直接进行新辅助化疗的预后

Ostby, Stuart A; Ainio, Chiara; Xu, Conway; Bruce, Kelly H; Block, Matthew S; Cliby, William A; Kumar, Amanika; Langstraat, Carrie L